Management of Mucositis with the Use of Leucovorin As Adjunct to Pralatrexate in Treatment of Peripheral T-Cell Lymphomas (PTCL) - Results from a Prospective Multicenter Phase 2 Clinical Trial

被引：3
|
作者：
Shustov, Andrei R. [1 ,2 ]
Shinohara, Michi M. [3 ]
Dakhil, Shaker R. [4 ]
Bhat, Gajanan [5 ]
Zain, Jasmine M. [6 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Univ Washington, Div Hematol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Dermatol, Seattle, WA 98195 USA
[4] Canc Ctr Kansas, Wichita, KS USA
[5] Spectrum Pharmaceut Inc, Irvine, CA USA
[6] City Hope Natl Med Ctr, Dept Hematol Hematopoiet Cell Transplantat, Duarte, CA USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-119684
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2910
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas:: first results of a prospective multicenter study
    Reimer, P
    Schertlin, T
    Rüdiger, T
    Geissinger, E
    Roth, S
    Kunzmann, V
    Weissinger, F
    Nerl, C
    Schmitz, N
    Müller-Hermelink, HK
    Wilhelm, M
    HEMATOLOGY JOURNAL, 2004, 5 (04) : 304 - 311
  • [42] Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial
    Mehta-Shah, Neha
    Zinzani, Pier Luigi
    Jacobsen, Eric D.
    Zain, Jasmine
    Mead, Monica
    Casulo, Carla
    Gritti, Giuseppe
    Pinter-Brown, Lauren C.
    Izutsu, Koji
    Bentur, Ohad S.
    Sidransky, David
    Brammer, Jonathan E.
    Pro, Barbara
    Fox, Christopher P.
    Horwitz, Steven
    BLOOD, 2024, 144 : 3061 - 3062
  • [43] Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial
    Haque, Tanzina
    Wilkie, Gwen M.
    Jones, Marie M.
    Higgins, Craig D.
    Urquhart, Gillian
    Wingate, Phoebe
    Burns, David
    McAulay, Karen
    Turner, Marc
    Bellamy, Christopher
    Amlot, Peter L.
    Kelly, Deirdre
    MacGilchrist, Alastair
    Gandhi, Maher K.
    Swerdlow, Anthony J.
    Crawford, Dorothy H.
    BLOOD, 2007, 110 (04) : 1123 - 1131
  • [44] Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study
    Liu, Xiao-Jian
    Guo, Ye
    Fan, Yun
    Gu, Kang-Sheng
    Cao, Jun-Ning
    Wu, Xiang-Hua
    Zhang, Jian
    Li, Xiao-Qiu
    Wang, Chao-Fu
    Hong, Xiao-Nan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) : 387 - 395
  • [45] Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study
    Xiao-Jian Liu
    Ye Guo
    Yun Fan
    Kang-Sheng Gu
    Jun-Ning Cao
    Xiang-Hua Wu
    Jian Zhang
    Xiao-Qiu Li
    Chao-Fu Wang
    Xiao-Nan Hong
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 387 - 395
  • [46] Safe and Effective Treatment of Patients with Peripheral T-Cell Lymphoma (PTCL) with the Novel HDAC Inhibitor, Belinostat, in Combination with CHOP: Results of the Bel-CHOP Phase 1 Trial
    Johnston, Patrick B.
    Cashen, Amanda F.
    Nikolinakos, Petros G.
    Beaven, Anne W.
    Barta, Stefan Klaus
    Bhat, Gajanan
    Song, Tao
    Choi, Mi Rim
    Allen, Lee F.
    de Vos, Sven
    Oki, Yasuhiro
    Deng, Changchun
    Foss, Francine M.
    BLOOD, 2015, 126 (23)
  • [47] Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis
    Brammer, Jonathan E.
    Zinzani, Pier Luigi
    Zain, Jasmine
    Mead, Monica
    Casulo, Carla
    Jacobsen, Eric D.
    Gritti, Giuseppe
    Litwak, Debra
    Cohan, David
    Katz, Danica J.
    Mehta-Shah, Neha
    Pro, Barbara
    Horwitz, Steven M.
    BLOOD, 2021, 138
  • [48] Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial
    Roberts, Nathan
    Lister, John
    Bennani, N. Nora
    Jain, Salvia
    Battaglia, Tammy
    Ayers, Emily C.
    Portell, Craig A.
    Williams, Michael E.
    Batchala, Prem
    Pal, Ipsita
    O'Connor, Owen A.
    Manavalan, John Sanil
    Marchi, Enrica
    BLOOD, 2022, 140 : 9425 - 9426
  • [49] Sufficient and Timely Autologous Stem Cell Harvest After Chemoimmunotherapy with Alemtuzumab In Combination with Bi-Weekly CHOP as First Line Treatment In Systemic Peripheral T-Cell Lymphomas (PTCL): a Feasibility Analysis From the First Randomized Trial In Systemic PTCL (ACT trial)
    d'Amore, Francesco
    da Silva, Maria Gomes
    Leppa, Sirpa
    Pezzutto, Antonio
    Relander, Thomas
    Lauritzsen, Grete Fossum
    Weidmann, Eckhart
    Van Gelder, Michel
    Doorduijn, Jeanette
    Kluin-Nelemans, J. C.
    Kooy, Marinus van Marwijk
    Fijnheer, Rob
    de Weerdt, Okke
    Brown, Peter de Nully
    Hansen, Per Boye
    Merup, Mats
    Grube, Matthias
    Mariz, Jose Mario
    Walewski, Jan
    Truemper, Lorenz
    Wulf, Gerald
    Jantunen, Esa
    Hopfinger, Georg
    Prochazka, Vit
    BLOOD, 2010, 116 (21) : 992 - 993
  • [50] Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial
    William, Basem M.
    Huang, Ying
    Johnson, Amy
    Brammer, Jonathan E.
    Reneau, John C.
    Maakaron, Joseph
    Larbi, Ruth
    Grantier, Cara
    Hoffman, Corinne
    Ayyappan, Sabarish
    Baiocchi, Robert A.
    Epperla, Narendranath
    Christian, Beth A.
    Alinari, Lapo
    Maddocks, Kami J.
    Chung, Catherine
    BLOOD, 2019, 134
12345